Vikas Prasad1, Nikolaus Tiling2, Timm Denecke3, Winfried Brenner4, Ursula Plöckinger2. 1. Department of Nuclear Medicine, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany. vikas.prasad@charite.de. 2. Interdisziplinären Stoffwechsel-Centrum, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany. 3. Department of Radiology, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany. 4. Department of Nuclear Medicine, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Abstract
PURPOSE: Neuroendocrine tumours of the pancreas (pNET) are observed in 8 - 17 % of patients with von Hippel-Lindau disease (vHLD), and 11 - 20 % of these patients develop metastatic disease. MRI and CT have a very high resolution; however, their sensitivity and specificity for the detection of pNET amongst cystic lesions in the pancreas of vHLD patients are generally considered insufficient. In contrast, (68)Ga-DOTATOC PET/CT demonstrates a high sensitivity for the diagnosis and staging of neuroendocrine tumours. In this study we investigated the potential role of (68)Ga-DOTATOC PET/CT in screening of patients with vHLD. METHOD: (68)Ga-DOTATOC PET/three-phase contrast-enhanced CT was performed according to guidelines in all consecutive vHLD patients between January 2012 and November 2015. All patients underwent additional MRI imaging of the abdomen, spine, and head. Chromogranin A (CgA) was determined at the time of the PET/CT examination. A lesion seen on (68)Ga-DOTATOC PET in the pancreas was defined as positive if the uptake was visually higher than in the surrounding tissues. Lesions were quantified using maximum SUV. RESULTS: Overall, 20 patients (8 men, 12 women; mean age 44.7 ± 11.1 years) were prospectively examined. Genetically, 12 patients had type 1 vHLD and 8 had type 2 vHLD. (68)Ga-DOTATOC PET/CT detected more pNET than morphological imaging (CT or MRI): 11 patients (55 %; 8 type 1, 3 type 2) vs. 9 patients (45 %; 6 type 1, 3 type 2). The concentration of CgA was mildly elevated in 2 of 11 patients with pNET. The mean SUVmax of the pancreatic lesions was 18.9 ± 21.9 (range 5.0 - 65.6). Four patients (36.4 %) had multiple pNETs. The mean size of the lesions on CT and/or MRI was 10.4 ± 8.3 mm (range 4 - 38 mm), and 41.1 % were larger than 10 mm. In addition, somatostatin receptor-positive cerebellar and spinal haemangioblastomas were detected in three patients (SUVmax 2.1 - 10.1). One patient presented with a solitary somatostatin receptor-positive lymph node metastasis. pNETs were observed more frequently in vHLD type 1 than type 2 (66.7 % vs. 37.5 %, p = 0.089). None of the patients showed progressive disease during follow-up. CONCLUSION: In this study, (68)Ga-DOTATOC PET detected pNETs in a higher proportion of patients with vHLD than found in previous studies with (111)In-octreoscan, the imaging method recommended by the NCCN. We therefore suggest (68)Ga-DOTATOC PET/CT as the more sensible screening tool.
PURPOSE:Neuroendocrine tumours of the pancreas (pNET) are observed in 8 - 17 % of patients with von Hippel-Lindau disease (vHLD), and 11 - 20 % of these patients develop metastatic disease. MRI and CT have a very high resolution; however, their sensitivity and specificity for the detection of pNET amongst cystic lesions in the pancreas of vHLDpatients are generally considered insufficient. In contrast, (68)Ga-DOTATOC PET/CT demonstrates a high sensitivity for the diagnosis and staging of neuroendocrine tumours. In this study we investigated the potential role of (68)Ga-DOTATOC PET/CT in screening of patients with vHLD. METHOD: (68)Ga-DOTATOC PET/three-phase contrast-enhanced CT was performed according to guidelines in all consecutive vHLD patients between January 2012 and November 2015. All patients underwent additional MRI imaging of the abdomen, spine, and head. Chromogranin A (CgA) was determined at the time of the PET/CT examination. A lesion seen on (68)Ga-DOTATOC PET in the pancreas was defined as positive if the uptake was visually higher than in the surrounding tissues. Lesions were quantified using maximum SUV. RESULTS: Overall, 20 patients (8 men, 12 women; mean age 44.7 ± 11.1 years) were prospectively examined. Genetically, 12 patients had type 1 vHLD and 8 had type 2 vHLD. (68)Ga-DOTATOC PET/CT detected more pNET than morphological imaging (CT or MRI): 11 patients (55 %; 8 type 1, 3 type 2) vs. 9 patients (45 %; 6 type 1, 3 type 2). The concentration of CgA was mildly elevated in 2 of 11 patients with pNET. The mean SUVmax of the pancreatic lesions was 18.9 ± 21.9 (range 5.0 - 65.6). Four patients (36.4 %) had multiple pNETs. The mean size of the lesions on CT and/or MRI was 10.4 ± 8.3 mm (range 4 - 38 mm), and 41.1 % were larger than 10 mm. In addition, somatostatin receptor-positive cerebellar and spinal haemangioblastomas were detected in three patients (SUVmax 2.1 - 10.1). One patient presented with a solitary somatostatin receptor-positive lymph node metastasis. pNETs were observed more frequently in vHLD type 1 than type 2 (66.7 % vs. 37.5 %, p = 0.089). None of the patients showed progressive disease during follow-up. CONCLUSION: In this study, (68)Ga-DOTATOC PET detected pNETs in a higher proportion of patients with vHLD than found in previous studies with (111)In-octreoscan, the imaging method recommended by the NCCN. We therefore suggest (68)Ga-DOTATOC PET/CT as the more sensible screening tool.
Entities:
Keywords:
68Ga-DOTATOC; PET/CT; SUVmax; von Hippel-Lindau disease
Authors: Hani B Marcos; Steven K Libutti; H Richard Alexander; Irina A Lubensky; David L Bartlett; McClellan M Walther; W Marston Linehan; Gladys M Glenn; Peter L Choyke Journal: Radiology Date: 2002-12 Impact factor: 11.105
Authors: Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti Journal: Eur J Nucl Med Mol Imaging Date: 2010-10 Impact factor: 9.236
Authors: M Pavel; D O'Toole; F Costa; J Capdevila; D Gross; R Kianmanesh; E Krenning; U Knigge; R Salazar; U-F Pape; K Öberg Journal: Neuroendocrinology Date: 2016-01-05 Impact factor: 4.914
Authors: Nils F Schreiter; Winfried Brenner; Munenobu Nogami; Ralph Buchert; Alexander Huppertz; Ulrich-Frank Pape; Vikas Prasad; Bernd Hamm; Martin H Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2011-09-17 Impact factor: 9.236
Authors: Mio Kitano; Corina Millo; Reza Rahbari; Peter Herscovitch; Krisana Gesuwan; Richard C Webb; Aradhana M Venkatesan; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Naris Nilubol; William M Linehan; Electron Kebebew Journal: Surgery Date: 2011-12 Impact factor: 3.982
Authors: P R Hammel; V Vilgrain; B Terris; A Penfornis; A Sauvanet; J M Correas; D Chauveau; A Balian; C Beigelman; D O'Toole; P Bernades; P Ruszniewski; S Richard Journal: Gastroenterology Date: 2000-10 Impact factor: 22.682
Authors: Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Sophie J van Asselt; Adrienne H Brouwers; Hendrik M van Dullemen; Eric J van der Jagt; Alfons H Bongaerts; Klaas P Koopmans; Ido P Kema; Bernard A Zonnenberg; Henri J Timmers; Wouter W de Herder; Wim J Sluiter; Elisabeth G de Vries; Thera P Links Journal: Eur J Endocrinol Date: 2016-02-16 Impact factor: 6.664
Authors: R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano Journal: J Endocrinol Invest Date: 2022-08-30 Impact factor: 5.467
Authors: Sven Gläsker; Evelynn Vergauwen; Christian A Koch; Alexander Kutikov; Alexander O Vortmeyer Journal: Onco Targets Ther Date: 2020-06-16 Impact factor: 4.147
Authors: Myrthe R Naber; Saya Ahmad; Annemarie A Verrijn Stuart; Rachel H Giles; Gerlof D Valk; Rachel S van Leeuwaarde Journal: J Endocr Soc Date: 2021-12-22